Valuation: Intervacc AB

Market Cap 446M 46.24M 40.45M 37.31M 34.46M 65.39M 4.41B 66.48M 175M 2.17B 174M 170M 7.47B P/E 2026 *
-5.95x
P/E 2027 * -5.95x
Enterprise Value 353M 36.6M 32.01M 29.53M 27.27M 51.74M 3.49B 52.61M 139M 1.72B 137M 134M 5.91B EV / Sales 2026 *
19.9x
EV / Sales 2027 * 12.7x
Free-Float
80.66%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 70 2026-02-04
Director of Finance/CFO - 2020-02-05
Chief Tech/Sci/R&D Officer - 2020-06-10
Director TitleAgeSince
Chairman 56 2026-05-12
Director/Board Member 72 2023-12-31
Director/Board Member 68 2024-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-4.14%-8.06%+58.96%+118.67% 54.63B
+1.84%-0.66%+59.82%+92.96% 54.88B
-2.24%+3.59%+17.75%+477.47% 25.06B
-1.60%-6.21%-18.96%-15.21% 23.14B
+2.43%+1.06%+42.44%-1.27% 19.88B
-3.19%0.00%+35.60%-26.98% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
-1.05%+1.16%+25.95%+194.27% 14.2B
+8.74%+3.51%+51.91%+726.40% 15.36B
Average -0.67%-0.28%+52.07%+213.72% 26.8B
Weighted average by Cap. -0.91%-1.46%+51.26%+176.25%

Financials

2026 *2027 *
Net sales 17.7M 1.84M 1.61M 1.48M 1.37M 2.6M 175M 2.64M 6.95M 86.27M 6.89M 6.74M 297M 30.05M 3.12M 2.73M 2.52M 2.32M 4.41M 297M 4.48M 11.8M 146M 11.7M 11.45M 504M
Net income -80.8M -8.38M -7.33M -6.76M -6.25M -11.85M -799M -12.05M -31.73M -394M -31.47M -30.79M -1.35B -83.65M -8.68M -7.59M -7M -6.47M -12.27M -828M -12.48M -32.85M -408M -32.58M -31.87M -1.4B
Net Debt -93M -9.65M -8.44M -7.78M -7.19M -13.64M -920M -13.87M -36.52M -453M -36.22M -35.44M -1.56B -63M -6.54M -5.72M -5.27M -4.87M -9.24M -623M -9.4M -24.74M -307M -24.54M -24M -1.06B
Logo Intervacc AB
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
Employees
-